论文部分内容阅读
目的：评价加速超分割放射治疗食管癌的疗效。方法：从１９９０年１０月至１９９２年５月我们对９８例经病理证实为食管鳞癌的患者进行了研究。随机分为常规组和加速超分割组。常规组：１８０～２００ｃＧｙ／次，５次／周，总量６０００～７０００ｃＧｙ／６～７周；加速超分割组：１５０ｃＧｙ／次，２次／日，间隔６小时以上，总量５４００ｃＧｙ／３．５周。两组患者均采用６０Ｃｏ远距离外照射。结果：常规组１，３，５年生存率分别为４６％（２３／５０）、２０％（１０／５０）、１２％（６／５０）；加速超分割组１，３，５年生存率分别为７０．８％（３４／４８）、３９．６％（１９／４８）、２９．２％（１４／４８），加速超分割组明显优于常规组（Ｐ＜０．０５），而两组放疗反应和并发症无明显差异。结论：我们的初步研究显示：加速超分割放疗能明显提高食管癌患者的生存率，但不增加放疗反应及并发症。
Objective: To evaluate the efficacy of accelerated hyperfractionated radiation therapy for esophageal cancer. METHODS: From October 1990 to May 1992 we studied 98 patients with pathologically confirmed esophageal squamous cell carcinoma. Randomly divided into conventional group and accelerated hyperfractionation group. Conventional group: 180 to 200 cGy/time, 5 times/week, total 6000 to 7000 cGy/6 to 7 weeks; accelerated hyperfractionation group: 150 cGy/time, 2 times/day, interval 6 hours or more, total 5400 cGy/3. 5 weeks. Both groups received 60Co long-distance external irradiation. Results: The 1-, 3-, and 5-year survival rates were 46% (23/50), 20% (10/50), and 12% (6/50) in the conventional group; 1, 3, and 5-year survival rates in the accelerated hyperfractionation group. They were 70.8% (34/48), 39.6% (19/48), and 29.2% (14/48), respectively. The accelerated hyperfractionation group was significantly better than the conventional group (P<0.05). There was no significant difference in radiotherapy response and complications between the two groups. Conclusion: Our preliminary study showed that accelerated hyperfractionated radiotherapy can significantly improve the survival rate of patients with esophageal cancer, but does not increase the radiotherapy response and complications.